Compare Ginkgo Bioworks Holdings Inc (DNA) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Revvity Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 22.2× Ginkgo Bioworks Holdings Inc's market cap, and Revvity Inc pays a 0.18% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Revvity Inc for 12 Days on average.
| DNA | RVTY | |
|---|---|---|
Market Cap | $763.64M | $16.98B |
Volume | 3,204,177 | 1,456,900 |
Sector | Health | Health |
52-Week High | $15.83 | $157.36 |
52-Week Low | $5.48 | $82.26 |
Typical Hold Time | 7 Days | 12 Days |
Enterprise Value | $865.59M | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.
The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
